AMAG Pharmaceuticals (AMAG) Receives Analyst Rating

AMAG Pharmaceuticals (AMAG) has an average broker rating of 1.86, which is interpreted as a Buy, as rated by 7 equity analysts. Nonetheless, 4 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 3 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.

AMAG Pharmaceuticals (AMAG) stock is expected to deviate a maximum of $18.88 from the average target price of $43.5 for the short term period. 6 Street Experts have initiated coverage on the stock with the most promising target being $80 and the most muted being $27.


Also, Jefferies maintains their rating on the shares of AMAG Pharmaceuticals (NASDAQ:AMAG). The current rating of the shares is Buy. Equity Analysts at the Firm lowers the price target to $45 per share from $58 per share. The rating by the firm was issued on August 11, 2016.

AMAG Pharmaceuticals (NASDAQ:AMAG): After opening at $24.09, the stock dipped to an intraday low of $23.94 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $24.98 and the buying power remained strong till the end. The stock closed at $24.9 for the day, a gain of 3.88% for the day session. The total traded volume was 687,835. The stocks close on the previous trading day was $23.97.

AMAG Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on maternal health, anemia and cancer supportive care. The Company markets Makena (hydroxyprogesterone caproate injection), Feraheme (ferumoxytol) Injection for Intravenous (IV) use and MuGard Mucoadhesive Oral Wound Rinse. Feraheme is an IV iron replacement therapy for the treatment of iron deficiency anemia (IDA) in adult patients with chronic kidney disease (CKD). Feraheme is approved for marketing in the United States. Makena is a drug indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth. MuGard is indicated for the management of oral mucositis/stomatitis and all types of oral wounds, including aphthous ulcers/canker sores and traumatic ulcers, such as those caused by oral surgery or ill-fitting dentures or braces.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.